Image_2_TGF-β phospho antibody array identifies altered SMAD2, PI3K/AKT/SMAD, and RAC signaling contribute to the pathogenesis of myxomatous mitral valve disease.TIF by Andrew J. McNair (9093310)

“…SMAD2 antagonism by siRNA and the SMAD7 agonist asiaticoside decreased detection of pSMAD by at least 50%, significantly decreased expression of the aVIC gene markers ACTA2, TAGLN, and MYH10, and pαSMA, pAKT2, and pERK1, but had no effect on pS6K, pERK2, or pVIM expression in aVICs. …”

Table_1_TGF-β phospho antibody array identifies altered SMAD2, PI3K/AKT/SMAD, and RAC signaling contribute to the pathogenesis of myxomatous mitral valve disease.docx by Andrew J. McNair (9093310)

“…SMAD2 antagonism by siRNA and the SMAD7 agonist asiaticoside decreased detection of pSMAD by at least 50%, significantly decreased expression of the aVIC gene markers ACTA2, TAGLN, and MYH10, and pαSMA, pAKT2, and pERK1, but had no effect on pS6K, pERK2, or pVIM expression in aVICs. …”

Image_3_TGF-β phospho antibody array identifies altered SMAD2, PI3K/AKT/SMAD, and RAC signaling contribute to the pathogenesis of myxomatous mitral valve disease.TIF by Andrew J. McNair (9093310)

“…SMAD2 antagonism by siRNA and the SMAD7 agonist asiaticoside decreased detection of pSMAD by at least 50%, significantly decreased expression of the aVIC gene markers ACTA2, TAGLN, and MYH10, and pαSMA, pAKT2, and pERK1, but had no effect on pS6K, pERK2, or pVIM expression in aVICs. …”

Data_Sheet_2_TGF-β phospho antibody array identifies altered SMAD2, PI3K/AKT/SMAD, and RAC signaling contribute to the pathogenesis of myxomatous mitral valve disease.docx by Andrew J. McNair (9093310)

“…SMAD2 antagonism by siRNA and the SMAD7 agonist asiaticoside decreased detection of pSMAD by at least 50%, significantly decreased expression of the aVIC gene markers ACTA2, TAGLN, and MYH10, and pαSMA, pAKT2, and pERK1, but had no effect on pS6K, pERK2, or pVIM expression in aVICs. …”

Image_1_TGF-β phospho antibody array identifies altered SMAD2, PI3K/AKT/SMAD, and RAC signaling contribute to the pathogenesis of myxomatous mitral valve disease.TIF by Andrew J. McNair (9093310)

“…SMAD2 antagonism by siRNA and the SMAD7 agonist asiaticoside decreased detection of pSMAD by at least 50%, significantly decreased expression of the aVIC gene markers ACTA2, TAGLN, and MYH10, and pαSMA, pAKT2, and pERK1, but had no effect on pS6K, pERK2, or pVIM expression in aVICs. …”

Data_Sheet_1_TGF-β phospho antibody array identifies altered SMAD2, PI3K/AKT/SMAD, and RAC signaling contribute to the pathogenesis of myxomatous mitral valve disease.docx by Andrew J. McNair (9093310)

“…SMAD2 antagonism by siRNA and the SMAD7 agonist asiaticoside decreased detection of pSMAD by at least 50%, significantly decreased expression of the aVIC gene markers ACTA2, TAGLN, and MYH10, and pαSMA, pAKT2, and pERK1, but had no effect on pS6K, pERK2, or pVIM expression in aVICs. …”

Simultaneous monitoring of cellular key characteristics during epithelial wound closure illustrated by results from a single measurement. by Dominik Bettenworth (626384)

“…(<b>C</b>) The average cell layer thickness as well as temporal thickness increase of mitomycin c-treated and unstimulated control was comparable while EGF-stimulated cell show a dramatically increased cell layer thickness that slightly decreased during the observation period. (<b>D</b>) The cellular volume <i>V</i> of mitomycin c-stimulated cells was constant during the 40 h observation period. …”

The ancestral mutant telomerase affects repeat addition processivity <i>in vitro</i>. by Jonathan K. Alder (225759)

“…Telomerase activity assay at high nucleotide (1 mM) concentrations on the left shows no defects in catalytic activity or processivity for hTERT V791I and V867M or the double mutant. At lower nucleotide concentration (10 µM), hTERT 867M and hTERT V791I-V867M both show defects in repeat addition processivity as evidenced by the decreased intensity of the high molecular weight products relative to the first repeat. …”

Increased CPEB4 protein level in most HCC specimens. by Li-Yun Tsai (503512)

“…(D) Fold change in CPEB4 and E-cad expression (T vs N) in each patient log2 transformed and plotted by tumor stage. Five of 8 CPEB4-downregulated samples with decreased expression of E-cadherin were denoted with number signs (#). …”

<i>In vitro</i> models of SMC phenotypic change. by Núria Coll-Bonfill (3151767)

“…Data are expressed as the mean ± SEM of five independent experiments performed in duplicate. …”

Influence of sampling accuracy on augmented reality for laparoscopic image-guided surgery by Andrea Teatini (9540508)

“…</p> <p> AR with intra-operative CT scanning showed a mean TRE of 6.9 mm for the machined phantom, 7.9 mm for the patient-specific phantom and 13.4 mm in the <i>in vivo</i> study.…”

Effects of an Oral Stimulation Program on Feeding Outcomes in Preterm Infants: A Systematic Review and Meta-Analysis by Elena Muñoz-Gómez (15654452)

“…Compared to usual care, unimodal sensorimotor stimulation protocols based on manual oral stimulation combined with NNS demonstrated to be more effective in decreasing time transition to FOF (standardized mean difference [95%CI] − 1.08 [−1.74, −0.41]), improving feeding efficacy (2.15 [1.18, 3.13]) and shortening length of hospital stay (−0.35 [−0.68, −0.03]). …”

Data Sheet 7_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo... by Xirui Xia (12075476)

“…</p>Results<p>The results show that compound 16C has low toxicity (LD₅₀ > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T_1/2kel) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”

Fig 1 - by Hiroko Nemoto (14227637)

“…<p><b>1A and 1B. Western blotting analysis comparing doxorubicin (DOX) samples with control (CTRL) samples.…”

Data Sheet 8_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo... by Xirui Xia (12075476)

“…</p>Results<p>The results show that compound 16C has low toxicity (LD₅₀ > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T_1/2kel) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”

Table1_Association between serum albumin creatinine ratio and all-cause mortality in intensive care unit patients with heart failure.docx by Jiuyi Wang (18969451)

“…Multivariate adjusted Cox regression and subgroup analysis demonstrated that individuals in Q2 [hazard ratio (HR) 0.82, 95%CI 0.71∼0.96], Q3 (HR 0.76, 95%CI 0.64∼0.91) and Q4 (HR 0.62, 95%CI 0.50∼0.76) had a decreased risk of mortality compared to individuals in Q1 (lower levels of sACR) (p for trend < 0.001), and this inverse relationship was consistently observed across various subgroups. …”

Image2_Modification of Fibronectin by Non-Enzymatic Glycation Impairs K+ Channel Function in Rat Cerebral Artery Smooth Muscle Cells.JPEG by Yan Yang (33204)

“…Bovine FN (1 mg/ml) was glycated (gFN) for 5 days using methylglyoxal (50 mM), and albumin was similarly glycated as a non-matrix protein control. …”

Data Sheet 4_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo... by Xirui Xia (12075476)

“…</p>Results<p>The results show that compound 16C has low toxicity (LD₅₀ > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T_1/2kel) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”

Clinical outcomes (MACE). by Tomohiko Shindo (612852)

“…The average weekly nitroglycerin use (times/week) was decreased from 5.50 to 2.44 in the LIPUS group and from 5.94 to 2.83 in the placebo group. …”

Baseline patient characteristics. by Tomohiko Shindo (612852)

“…The average weekly nitroglycerin use (times/week) was decreased from 5.50 to 2.44 in the LIPUS group and from 5.94 to 2.83 in the placebo group. …”